Efficacy and safety of efpeglenatide in key patient subgroups from the BALANCE randomized trial, stratified by pre-diabetes status, BMI, and age at baseline

• John Stewart,
• Richard E Pratley,
• Marcus Hompesch,
• OakPil Han,
• Michael E Trautmann,
• Christopher H Sorli,
• SeungJae Baek,
• Stephan Jacob,
• Alka Shaunik,
• Kun-Ho Yoon

Affiliations

John Stewart

Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Richard E Pratley

AdventHealth Translational Research Institute, Orlando, Florida, USA

Marcus Hompesch

Clinical Investigation, ProSciento Inc, Chula Vista, California, USA

OakPil Han

Hanmi Pharmaceutical Co., Ltd, Seoul, Republic of Korea

Michael E Trautmann

Clinical Investigation, ProSciento Inc, Chula Vista, California, USA

Christopher H Sorli

Sanofi, Bridgewater, New Jersey, USA

SeungJae Baek

11Hanmi Pharmaceutical Co., Ltd., Seoul, Korea, Republic of

Stephan Jacob

Cardio-Metabolic-Institute, Praxis für Prävention und Therapie, Villingen-Schwenningen, Germany

Alka Shaunik

Sanofi, Bridgewater, New Jersey, USA

Kun-Ho Yoon

Seoul St Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea